A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 1
- Registration Number
- NCT05351554
- Locations
- 🇺🇸
Kinevant Study Site, Charleston, South Carolina, United States
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 107
- Registration Number
- NCT05314517
- Locations
- 🇬🇧
Kinevant Study Site, London, United Kingdom
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 227
- Registration Number
- NCT04351243
- Locations
- 🇺🇸
Banner University Medical Center, Tucson, Arizona, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT04205851
- Locations
- 🇨🇦
Altasciences Clinical Research, Montréal, Quebec, Canada
© Copyright 2024. All Rights Reserved by MedPath